We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 60

India’s guidance for biosimilar drugs draws cautious industry welcome
  • Shook Hardy & Bacon LLP
  • India
  • September 20 2012

According to a news source, industry has given India’s new guidelines for biosimilar drugs, launched August 15, 2012, a “cautious welcome.”


Indian biotech association signs MOU with U.S.-based association
  • Shook Hardy & Bacon LLP
  • India, USA
  • October 18 2012

The Association of Biotechnology Led Enterprises (ABLE), representing biotechnology interests in India, has reportedly signed a memorandum of understanding (MOU) with the Washington Biotechnology and Biomedical Association (WBBA), Washington state’s life-sciences trade association


Indian drug industry disputes prohibition on brand names
  • Shook Hardy & Bacon LLP
  • India
  • November 1 2012

According to a news source, the Indian Drugs Manufacturing Association is gearing up to challenge action taken by the country’s drug controller to prevent the sale of medicines under brand names as part of an effort to accelerate sales of less-expensive generics


Scientists oppose SCI’s recommended moratorium on biotech crops
  • Shook Hardy & Bacon LLP
  • India
  • November 1 2012

After an expert committee appointed by the Supreme Court of India (SCI) recommended halting field trials of transgenic food crops for 10 years, biotechnologists, agricultural scientists and agribiotech-industry heads reportedly gathered in Bangalore to oppose the recommendations


India-based company’s drugs barred from U.S. market
  • Shook Hardy & Bacon LLP
  • India, USA
  • January 30 2014

The U.S. Food and Drug Administration (FDA) has prohibited imported drug products from a Ranbaxy Laboratories, Inc. facility in India due to


India Supreme Court requests removal of industry reps from safety enforcement panels
  • Shook Hardy & Bacon LLP
  • India
  • February 11 2011

Ruling on a request by a non-governmental organization (NGO), two supreme court justices in India have reportedly asked the government to remove food and soft drink company representatives from food-safety standards and enforcement panels


India biotech sector set to reach $10 billion by 2015
  • Shook Hardy & Bacon LLP
  • India
  • May 19 2011

According to a news source, India's biotechnology sector is expected to reach $10 billion in revenue by 2015


Drug launch within six months of controller general approval now required in India
  • Shook Hardy & Bacon LLP
  • India
  • January 24 2013

According to a news source, the Drugs Controller General of India (CG) has announced that pharmaceutical companies failing to launch their drugs


India’s biotechnology regulatory bill faces opposition
  • Shook Hardy & Bacon LLP
  • India
  • November 17 2011

According to a news source, the proposed Biotechnology Regulatory Authority of India Bill, 2011, was withdrawn from the Monsoon Session of Parliament after congressional members and others objected to placing the new regulatory agency under the authority of the Ministry of Science & Technology


Indian official calls for passage of biotech regulatory legislation and increased VC funding
  • Shook Hardy & Bacon LLP
  • India
  • February 16 2012

A biotechnology industry spokesperson has reportedly pointed to the lack of a proper regulatory framework in India as one of several hurdles the industry will have to surmount to grow